Insider Selling: Biohaven Pharmaceutical Holding Co Ltd (BHVN) Director Sells 40,000 Shares of Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $26.52, for a total transaction of $1,060,800.00. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Gregory Bailey also recently made the following trade(s):

  • On Thursday, January 4th, Gregory Bailey sold 50,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $28.71, for a total transaction of $1,435,500.00.
  • On Wednesday, December 20th, Gregory Bailey sold 39,430 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $26.31, for a total transaction of $1,037,403.30.
  • On Thursday, November 30th, Gregory Bailey sold 9,970 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $25.48, for a total transaction of $254,035.60.
  • On Friday, November 24th, Gregory Bailey sold 600 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $26.02, for a total transaction of $15,612.00.
  • On Monday, November 27th, Gregory Bailey sold 20,600 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $25.92, for a total transaction of $533,952.00.

Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE BHVN) traded up $2.05 during trading on Thursday, hitting $28.97. 442,538 shares of the stock were exchanged, compared to its average volume of 370,194. The firm has a market cap of $1,210.00 and a PE ratio of -5.55. Biohaven Pharmaceutical Holding Co Ltd has a fifty-two week low of $17.00 and a fifty-two week high of $39.51.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($1.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.03. sell-side analysts forecast that Biohaven Pharmaceutical Holding Co Ltd will post -6.4 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on the stock. BidaskClub raised shares of Biohaven Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 28th. Morgan Stanley lifted their target price on shares of Biohaven Pharmaceutical from $28.00 to $47.00 and gave the company an “overweight” rating in a report on Monday, September 25th. William Blair reaffirmed an “outperform” rating on shares of Biohaven Pharmaceutical in a report on Tuesday, October 3rd. Needham & Company LLC cut their target price on shares of Biohaven Pharmaceutical from $43.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, October 3rd. Finally, Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $36.14.

A number of institutional investors and hedge funds have recently made changes to their positions in BHVN. Legal & General Group Plc acquired a new position in Biohaven Pharmaceutical in the 3rd quarter valued at $119,000. Nationwide Fund Advisors acquired a new position in Biohaven Pharmaceutical in the 3rd quarter valued at $214,000. American International Group Inc. acquired a new position in Biohaven Pharmaceutical in the 3rd quarter valued at $251,000. State of Wisconsin Investment Board acquired a new position in Biohaven Pharmaceutical in the 3rd quarter valued at $262,000. Finally, Susquehanna International Group LLP acquired a new position in Biohaven Pharmaceutical in the 3rd quarter valued at $302,000. 47.76% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.truebluetribune.com/2018/01/18/insider-selling-biohaven-pharmaceutical-holding-co-ltd-bhvn-director-sells-40000-shares-of-stock.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply